Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2017

View Archived Issues

Therapix Biosciences begins nonclinical studies of THX-150

Shire offers overview of pipeline developments in third quarter 2017

AbbVie reflects on accomplishments of third quarter 2017

CB-1763 demonstrates excellent antitumor activity in BTK driven-xenograft mouse model

Impel Neuropharma doses first patient in phase I study of INP-104

Akcea Therapeutics reports positive data from phase I/IIa study of AKCEA-APOCIII-LRx

Second-generation PSMA ligands 177Lu-RPS-068 and 177Lu-RPS-063 show increased tumor uptake

Novel LIF/LIFR inhibitor EC-359 demonstrates therapeutic potential in preclinical cancer models

European Commission grants orphan drug status to Agilis' AGIL-FA

Rice University discovers novel viridicatumtoxin B analogues

New ALK tyrosine kinase receptor inhibitors identified at Blueprint Medicines

Skyline Antiinfectives patents new deuterated monobactam antibiotics

Cancer Research Technology presents novel RET kinase inhibitors

RegeneRx reports results from ARISE-2 study of RGN-259

Esteve identifies novel dual sigma1 and mu opioid receptor ligands

FDA gives fast track designation to imetelstat for lower risk MDS

Incyte and AstraZeneca expand clinical collaboration to study epacadostat and durvalumab in NSCLC

Calquence approved and available to order in U.S. for mantle cell lymphoma

EA Pharma signs Korean license agreement with JW Pharmaceutical for AJT-240

Veloce BioPharma initiates phase II trial of VBP-926 for chemotherapy-associated paronychia

Sanofi, Regeneron report positive results from phase III study of dupilumab in asthma

Visterra receives fast track status from FDA for VIS-410

FDA awards rare pediatric disease designation to ArQule's miransertib

T-025 demonstrates antitumor activity via the MDM4-p53 pathway

New phase II trial investigates SPI-1005 for bipolar disorder

FDA awards breakthrough therapy designation to GSK-2857916 for multiple myeloma

Sarepta Therapeutics and Duke University enter CRISPR/Cas9 technology license agreement

Novel ADC for the treatment of colorectal cancers and other GI malignancies

Symic Bio reports results from SHIELD study of SB-030 in peripheral vascular disease

FDA committee recommends approval of Braeburn Pharmaceuticals' CAM-2038 for opioid use disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...